Medtronic's Cash Machine Is Accelerating While the Stock Still Looks Defeated

Medtronic stock hit a 52-week low of $73.31 earlier this year — roughly 30% below its high. It's still trading around $91, down roughly 6% year-to-date, and investors who've been watching have had every reason to feel the wait. Tariff uncertainty. A diabetes spinoff adding complexity. Questions about whether mid-single-digit revenue growth could ever translate into real earnings leverage.

Then the fiscal year closed. Medtronic delivered $36.4 billion in revenue — its highest annual growth in ten years. Free cash flow over the trailing twelve months sits at $6.1 billion, up nearly 16% from the prior year. And for the coming fiscal year, management guided to 6.75%–7.25% organic revenue growth and $5.90–$6.00 in non-GAAP EPS, a 6.7%–8.5% step up.

The operating trajectory has clearly shifted. The question for investors is whether the stock has caught up to that shift — or whether the old story is still holding the price down.

What Changed

Medtronic spent years chasing growth in a way that never quite stuck. Revenue trends were flat or modest. The stock underperformed peers. Investors categorized it as the reliable-but-boring medtech dividend play — the kind of company you own for yield and forget about for capital appreciation.

The change is concentrated in one area: cardiovascular ablation, specifically a technology called pulsed field ablation, or PFA. This is a newer approach to treating atrial fibrillation — the most common serious heart rhythm disorder — that uses electrical fields rather than heat to destroy problematic heart tissue. It's faster, safer, and the market is embracing it quickly. The global PFA market is estimated to grow from roughly $910 million in 2024 to $6.2 billion by 2030.

Medtronic's Cardiac Ablation Solutions grew 71% in fiscal Q2, 80% in Q3, and 78% in Q4 — with U.S. growth hitting 124% in the final quarter. The cardiovascular portfolio as a whole grew 9.3% organically for the full year, the strongest performance in over a decade excluding the pandemic. That single segment went from one component of a diversified portfolio to the engine pulling the entire company forward.

The rest of the business hasn't stalled. Neuroscience grew 3% organically, medical surgical rose 4.9%, and the company is layering in additional growth from acquisitions like CathWorks in renal denervation and pipeline products including Hugo robotic-assisted surgery and Stealth AXiS in spine.

The Free Cash Flow Bridge

Revenue growth is the headline. Free cash flow is what tells you whether a company can actually finance its own future.

Medtronic's TTM free cash flow of $6.1 billion grew 15.6% year-over-year. That's the acceleration that matters more than the revenue number alone. The company generated $8.0 billion in operating cash flow while holding capital expenditures to $1.9 billion — a clean cash conversion ratio. FCF margin sits at 14.9%, up from roughly 13% a year ago.

Return on invested capital is 14.2%. Return on equity is 21.8%. These are not stagnant numbers. They're the returns of a business where growth and efficiency are moving in the same direction.

For the coming fiscal year, management guided to $5.90–$6.00 in non-GAAP EPS, up roughly 8% from the $5.53 reported for FY26. On the implied midpoint of $5.95, the current $91 stock price trades at roughly 15.3x forward non-GAAP earnings. If free cash flow continues its trajectory at roughly $6.7 billion for the coming year — a reasonable extrapolation given the 15.6% growth rate and the margin expansion — the market cap of $116 billion implies roughly 17x forward FCF.

That's not cheap for medtech. But it's not pricing in a high-growth company either. It's pricing a company the market still believes is growing in the mid-single digits, not one that just delivered ten-year-best revenue growth and guided to nearly 7% organic expansion.

Why the Stock Hasn't Fully Moved

This is where the expectations-reset contrast shows up. The market is still pricing the old risk profile while the operating setup is already getting cleaner.

Three factors are keeping the stock anchored:

First, the MiniMed diabetes spinoff. Management announced plans to separate the diabetes business into a publicly traded company within roughly 15 months. That adds near-term earnings uncertainty and portfolio complexity — not because the underlying diabetes business is bad (it grew 8.3% organically in FY26), but because spinoffs create a period of opacity that investors dislike.

Second, tariff headwinds. Management has built approximately $185 million in tariff-related costs into its guidance. That's a real drag, and it shows up as a line item that investors will watch for expansion risk.

Third, the market needs more than one good year. Truist maintains a Hold on the stock, seeking stronger EPS growth over multiple quarters before declaring the turnaround complete. That's a fair position — a single acceleration year doesn't erase years of underperformance. But it also means the bar for surprise is genuinely low. Management has raised guidance every quarter this fiscal year, and each time the stock's reaction was muted at best.

UBS recently upgraded the stock to Buy, arguing the turnaround is underway. The split in analyst opinion itself is part of the setup: the numbers are improving, but not everyone has updated their mental model yet.

What Would Break the Case

The thesis here depends on the operating momentum continuing, not reversing. The break condition is specific: Medtronic guided to 6.75%–7.25% organic revenue growth and $5.90–$6.00 non-GAAP EPS for FY27. If the company comes in at the bottom of that range or below — particularly if the PFA growth curve flattens back toward the low-50s percentage range rather than maintaining the 70%–80% trajectory — the rerating argument loses its foundation.

Tariff expansion is the second risk. The $185 million already priced into guidance could grow if trade policy tightens further, eating directly into margins and FCF. That would narrow the gap between the old story and the new one.

The MiniMed separation adds a third layer of execution risk. A messy IPO process or a weaker-than-expected valuation for the spun-off unit could create accounting complexity and investor confusion around the remaining consolidated results.

These are real risks, not hypotheticals. But they're execution risks against a business that is, at the operating level, genuinely improving.

The Investment Case

This is not about excitement. It is about a business that may soon look a lot harder to dismiss once the free cash flow compounding becomes undeniable.

Medtronic has the characteristics of an expectations-reset name: the market has already discounted the company as slow-growth medtech, while the underlying operations are accelerating on a credible technology platform with a multi-year runway. PFA is not a one-year product cycle. The global addressable market for atrial fibrillation treatment is measured in millions of patients, and Medtronic's market share is growing — up 8 points in the U.S. during Q4 alone.

The forward multiples don't scream bargain. But they also don't reflect a company that just guided to nearly 7% organic growth, raised EPS guidance every quarter for a fiscal year, and expanded free cash flow by 16%. The gap between what the numbers show and what the price implies is narrowing but hasn't closed.

The next two quarters of fiscal 2027 will determine whether this inflection is durable or a one-year event. If revenue growth holds near the midpoint of guidance and FCF continues compounding, the stock should have room to rerate toward the multiples of medtech peers that are already being viewed as growth stories. If it doesn't, the old story survives — and there's nothing wrong with walking away when the proof point fails to arrive.

The setup is a company with $6.1 billion in trailing free cash flow, growing faster than its revenue, guided to grow faster still. The stock hasn't fully caught up. That's the asymmetry. Whether it's enough to act on depends on your conviction that PFA and the broader cardiovascular portfolio can sustain the momentum — and your tolerance for waiting while the market updates its mind, one quarter at a time.